About Allarity Therapeutics
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs.
The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology.
Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer.
The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment.
Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.